MedTrace Logo

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

NCT07594119 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 312

Last updated 2026-05-18

No results posted yet for this study

Summary

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Conditions

Interventions

DRUG

RAP-219

RAP-219 medium dose tablets administered orally daily

DRUG

RAP-219

RAP-219 low dose tablets administered orally daily

OTHER

Placebo

Matching placebo tablets administered orally

Sponsors & Collaborators

  • Rapport Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Vicente Villaneuva, M.D., PhD · Hospital Universitari i Politecnic La Fe, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-07-31
Completion
2029-09-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07594119 on ClinicalTrials.gov